Recent Interferon Current Events | Interferon News
|
| Page
1 of
6 |
119 Results |
|
|
|
Sort By:
Relevance | Page Views |
Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study. view more (2009-11-02)
Discovery could improve hepatitis C treatment
Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments. view more (2009-09-24)
Researchers prolong the plasma half-life of biopharmaceutical proteins
Many biopharmaceuticals comprise small proteins that are quickly eliminated from the body. Scientists at the Technische Universitaet Muenchen (TUM) combine such small proteins with a kind of molecular balloon that swells and thus prolongs the half-life of the proteins in the body. view more (2009-09-21)
Fewer injection site reactions in patients using Avonex
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon® (interferon beta-1b), Copaxone® (glatiramer Acetate) or Rebif ®... view more... (2009-09-11)
Current hepatitis C treatments work equally well, UT Southwestern and national researchers report
The three treatment combinations for clearing the most common form of the hepatitis C virus work equally well with similar side effects, UT Southwestern Medical Center researchers and their colleagues in 13 other institutions have found. view more (2009-08-07)
Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells
An international team of researchers has identified a new method for selectively killing metastatic melanoma cells, which may lead to new areas for drug development in melanoma - a cancer that is highly resistant to current treatment strategies. view more (2009-08-04)
The right messenger for a healthy immune response
Researchers from the Molecular Immunology group at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now shown that Beta-Interferon also plays a crucial role during an immune response: without Beta-Interferon immune cells are unable to show "wanted posters" of pathogens to other cells. view more (2009-07-20)
UT researcher: Interferon alpha can delay full onset of type I diabetes
A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes. view more (2009-07-01)
Good news for some hard-to-treat hepatitis C patients
In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment. view more (2009-06-16)
Immunologists identify biochemical signals that help immune cells remember how to fight infection
Immunology researchers at UT Southwestern Medical Center have discovered how two biochemical signals play unique roles in promoting the development of a group of immune cells employed as tactical assassins. view more (2009-05-29)
Immunologists identify biochemical signals that help immune cells remember how to fight infection
Immunology researchers at UT Southwestern Medical Center have discovered how two biochemical signals play unique roles in promoting the development of a group of immune cells employed as tactical assassins. view more (2009-05-28)
Hyperferritinemia is another surrogate marker of advanced liver disease
High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients. view more (2009-05-13)
Adding steroid drug to MS treatment may reduce disease activity
Using a steroid drug for multiple sclerosis (MS) in addition to an MS drug may reduce the amount of disease activity more than using the MS drug alone. view more (2009-04-30)
Team identifies a molecular switch linking infectious disease and depression
Researchers at the University of Illinois report that IDO, an enzyme found throughout the body and long suspected of playing a role in depression, is in fact essential to the onset of depressive symptoms sparked by chronic inflammation. view more (2009-04-01)
Mutations within a conservative region of HCV affects the therapy
At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide. Approximately 30%-50% of patients respond to interferon/ribavirin combination therapy. view more (2009-03-31)
A potential therapeutic strategy for hepatic failure
Fulminant hepatic failure is a serious clinical disease and may threaten the life of patients. However, because of the damage of mass liver cells, the organ function is often irreversible due to the liver cell degeneration, swelling, or apoptosis. Thus, to supply new sources of functional liver cells is a valuable choice for these patients. view more (2009-03-31)
2-day results predict ultimate response to therapy in chronic hepatitis C
A new study suggests that previously noted low rates of successful hepatitis C virus (HCV) therapy in African Americans are in large part due to very early differences in the antiviral activity induced by interferon. view more (2009-03-23)
Stem cells could halt osteoporosis, promote bone growth
While interferon gamma sounds like an outer space weapon, it's actually a hormone produced by our own bodies, and it holds great promise to repair bones affected by osteoporosis. view more (2009-03-05)
New discovery gives tuberculosis vaccine a shot in the arm
A new article appearing in the March 2009 issue of the Journal of Leukocyte Biology may lead to improvements in the efficacy of the current tuberculosis vaccine. view more (2009-02-27)
Stem cells: Deathly awakening by interferon
After injuries with blood loss, the body quickly needs to restore the vital blood volume. This is accomplished by a special group of stem cells in the bone marrow. view more (2009-02-12)
|
|
| Page
1 of
6 |
119 Results |
|
|
|
Sort By:
Relevance | Page Views |
|
